D. Goldstein

发表

A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.

S Shen, G L DeNardo, K. Lamborn, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.

G. Denardo, S. Denardo, S. Shen, 1998, Anticancer research.

Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies

K. Lamborn, G. Denardo, S. Denardo, 2006, Cancer Immunology, Immunotherapy.

Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.

G. Denardo, S. Denardo, S. Shen, 1997, Anticancer research.

Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies.

K. Lamborn, G. Denardo, S. Denardo, 1994, Cancer research.

Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.

L. Fehrenbacher, P. Lara, H. West, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Strategies for developing effective radioimmunotherapy for solid tumors.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Radioimmunotherapy with 111in/90y-2it-BAD-m170 for metastatic prostate cancer

G. Denardo, S. Denardo, S. Shen, 2001 .

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.

F. Meyers, G. Denardo, S. Denardo, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.

G. Denardo, S. Denardo, S. Shen, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.

K. Lamborn, G. Denardo, S. Denardo, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Anticancer research.

Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.

K. Lamborn, G. Denardo, S. Denardo, 1997, Anticancer research.

Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.

G. Denardo, S. Denardo, S. Shen, 2003, Cancer biotherapy & radiopharmaceuticals.

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

J. McGahan, K. Lamborn, G. Denardo, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia

G L DeNardo, K. Lamborn, G. Denardo, 1997, Cancer.

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.

J. McGahan, K. Lamborn, G. Denardo, 1998, Cancer biotherapy & radiopharmaceuticals.

Computed Tomography Radiomics Signatures: Sensitive biomarkers for clinical decision support in pancreatic cancer- a pilot study

V. Gebski, A. Barbour, A. Habibalahi, 2021, medRxiv.

High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody

K. Lamborn, G. Denardo, S. Denardo, 2005, Clinical Cancer Research.

Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.

K. Lamborn, O. Schillaci, G. Denardo, 2007, Cancer biotherapy & radiopharmaceuticals.

Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Clinical lymphoma.

Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.

G. Denardo, S. Shen, D. Kukis, 1999, Cancer biotherapy & radiopharmaceuticals.

Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies.

K. Lamborn, G. Denardo, S. Denardo, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.